FDA gets a dietary supplement registry—finally, a public database of what's in your pills
S. 3677 — Dietary Supplement Listing Act of 2026 · Filed by Richard Durbin (D-IL) · Introduced Jan 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires dietary supplement manufacturers to register their products with the FDA and submit detailed ingredient, labeling, and business information. Existing supplements have 18 months to register; new ones must register before sale. The FDA will maintain a public database of most information (keeping proprietary blend amounts and facility locations confidential) and assign each product a listing number. Manufacturers who fail to register or update listings face penalties under food-safety law.
Why we flagged it
The bill's core mechanism is a mandatory registration and listing system for dietary supplements sold in the US, with public disclosure of most product information. This is a regulatory transparency measure, not a subsidy, carve-out, or deregulation.
What the text implies
- The 18-month compliance window for existing products may create a temporary surge in FDA administrative work and potential bottlenecks in processing listings, which could delay enforcement of other FDA priorities.
- Proprietary blend amounts remain confidential, meaning consumers cannot fully verify ingredient quantities—a significant limitation on transparency that may reduce the practical value of the public database for informed comparison.
- The bill does not grant the FDA authority to pre-approve supplements or reject listings based on safety; it is a registration system only. Unsafe products can still be listed and sold unless the FDA takes separate enforcement action.
- Small dietary supplement manufacturers may face disproportionate compliance costs (legal, IT, administrative) relative to large competitors, potentially consolidating the market toward larger players.
- The electronic database and listing numbers may enable future regulatory action (e.g., recalls, restrictions) more efficiently, but the bill itself does not authorize such action—it is a data-collection foundation.
Who it affects
Ordinary consumers gain transparency about what is in dietary supplements and who makes them—information currently unavailable. The public database enables comparison shopping and helps identify unsafe products. The confidentiality carve-outs for proprietary blends and facility locations are narrow and do not eliminate the core benefit. Compliance costs fall on manufacturers, not consumers.
Who stands to gain
- large dietary supplement manufacturers (lower relative compliance cost, competitive advantage)
- FDA (expanded regulatory capacity and data infrastructure)
- software/IT vendors (database development and compliance-tracking tools)
Named in the bill
FDA (Food and Drug Administration), dietary supplement manufacturers, dietary supplement industry, Federal Food, Drug, and Cosmetic Act, Section 403D (new), Section 301 (amended), proprietary blends
Where it stands
- Jan 15, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jan 15, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S259-260)”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
4 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $470,000 in lobbying spend. A filing names 6 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 72% of bills with at least one filing.
Richard Durbin, the sponsor, reported $-29,800 in PAC receipts in the 2026 cycle.
- Haleon Us Holdings LLC — $260,000 on 1 filing
- Council for Responsible Nutrition — $100,000 on 1 filing
- Pharmavite LLC — $90,000 on 1 filing
- Doterra International LLC — $20,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 5, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA gets a dietary supplement registry—finally, a public database of what's in your pills” QuorumCivic. https://share.quorumcivic.app/bill/119/s3677 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.